Compare MRCY & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCY | BLLN |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.8B |
| IPO Year | 1997 | N/A |
| Metric | MRCY | BLLN |
|---|---|---|
| Price | $98.92 | $133.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $80.00 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 620.6K | 588.5K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $912,020,000.00 | N/A |
| Revenue This Year | $6.59 | $46.29 |
| Revenue Next Year | $9.56 | $30.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.19 | N/A |
| 52 Week Low | $50.13 | $61.96 |
| 52 Week High | $128.45 | $138.70 |
| Indicator | MRCY | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 63.49 |
| Support Level | $70.51 | $79.07 |
| Resistance Level | $103.81 | $138.70 |
| Average True Range (ATR) | 5.63 | 7.32 |
| MACD | -0.46 | -0.64 |
| Stochastic Oscillator | 28.34 | 97.01 |
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.